Q-omics provides the consensus-scored AMOTL1 profile across patient tissues and cancer cell-line models. AMOTL1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, AMOTL1 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, AMOTL1 protein abundance shows 20,272 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight KIRC, BLCA, and UCEC as cancer lineages where AMOTL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AMOTL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AMOTL1 survival associations across molecular data types. AMOTL1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AMOTL1 RNA expression–survival associations across cancer types. High AMOTL1 expression shows unfavorable associations in BLCA and UVM, but favorable associations in KIRC, UCS, ESCA and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for AMOTL1 RNA expression.
This table summarizes AMOTL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for AMOTL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AMOTL1 shows lower tumor expression in BLCA, LUAD, THCA, COAD and BRCA and higher tumor expression in KIRC. The BLCA box plot shows higher AMOTL1 RNA expression in normal versus tumor tissue (log2 FC = −1.557, t-test p < 0.001).
This table shows molecular features associated with AMOTL1 in patient tissues and cancer cell lines. In patient samples, AMOTL1 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, AMOTL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
